Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 700 of 1048 entries
View as:

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT03251313 Org: User:
Start: 05/15/19 End: 12/30/22 Due: 12/30/23

Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV

Phase: N/A Priority: Normal
NCT ID: NCT06560840 Org: User:
Start: 08/20/24 End: 05/20/25 Due: 05/20/26

Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00999843 Org: User:
Start: 10/31/09 End: 10/31/12 Due: 10/31/13

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04517214 Org: User:
Start: 11/01/20 End: 12/31/26 Due: 12/31/27

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Phase: N/A Priority: Normal
NCT ID: NCT05311319 Org: User:
Start: 01/11/22 End: 12/31/23 Due: 12/31/24

QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01796782 Org: User:
Start: 01/31/13 End: 12/31/15 Due: 12/31/16

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05010681 Org: User:
Start: 08/24/21 End: 08/20/25 Due: 08/20/26

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04592666 Org: User:
Start: 10/09/20 End: 06/30/22 Due: 06/30/23

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT06561620 Org: User:
Start: 05/01/24 End: 05/01/29 Due: 05/01/30

Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy

Phase: N/A Priority: Normal
NCT ID: NCT01731821 Org: User:
Start: 10/31/12 End: 10/31/14 Due: 10/31/15

The Rechallenge of ADCs in MBC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05571618 Org: User:
Start: 09/01/22 End: 03/01/25 Due: 03/01/26

Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy

Phase: N/A Priority: Normal
NCT ID: NCT00890409 Org: User:
Start: 05/31/02 End: 08/31/05 Due: 08/31/06

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05975749 Org: User:
Start: 01/01/23 End: 01/01/29 Due: 01/01/30

Everolimus Related Pneumonitis in MBC

Phase: N/A Priority: Normal
NCT ID: NCT03730428 Org: User:
Start: 07/15/17 End: 06/15/20 Due: 06/15/21

Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00868569 Org: User:
Start: 01/31/08 End: 12/31/10 Due: 12/31/11

Heating Precondition of Streamlined Liner of the Pharynx Airway Decrease the Incidence of Sore Throat

Phase: N/A Priority: Normal
NCT ID: NCT02539485 Org: User:
Start: 06/30/15 End: - Due: -

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01924078 Org: User:
Start: 10/31/10 End: 06/30/15 Due: 06/30/16

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03151447 Org: User:
Start: 03/06/17 End: 03/31/18 Due: 03/31/19

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase: N/A Priority: Normal
NCT ID: NCT06323148 Org: User:
Start: 04/01/24 End: 03/31/29 Due: 03/31/30

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04508816 Org: User:
Start: 01/01/16 End: 10/01/20 Due: 10/01/21

Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone

Phase: N/A Priority: Normal
NCT ID: NCT03988686 Org: User:
Start: 04/01/19 End: 03/31/22 Due: 03/31/23

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Phase: N/A Priority: Normal
NCT ID: NCT06170216 Org: User:
Start: 01/10/23 End: 01/10/26 Due: 01/10/27

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06548178 Org: User:
Start: 09/30/24 End: 09/30/28 Due: 09/30/29

Ozone Reaction Products and Skin Health

Phase: N/A Priority: Normal
NCT ID: NCT06932419 Org: User:
Start: 04/30/25 End: 12/31/26 Due: 12/31/27

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Phase: N/A Priority: Normal
NCT ID: NCT07021261 Org: User:
Start: 06/16/25 End: 06/16/32 Due: 06/16/33